Skip to main content
SpringerLink
Log in

Role of Blood Bank, Transfusion Services, and Pharmacy in ICU Patients with Hematologic Challenges

  • Chapter
  • First Online:
Hematologic Challenges in the Critically Ill

  • 657 Accesses

Abstract

The practice of pharmacy and transfusion medicine is evolving rapidly in the face of a new era of healthcare calling for improved quality of care and better outcomes with lower costs. A better understanding of the principles of Patient Blood Management (PBM) and the relating therapies that are dispensed from both the pharmacy and the blood bank is a requisite for collaborating healthcare practitioners to be able to fulfill their new role as active members of healthcare teams. The traditional view on allogeneic blood transfusion as a “lifesaving” treatment has been shattered as evidence on harms of unwarranted transfusions, costs, and dwindling supplies emerges. The core tenets of PBM call for a multidisciplinary care strategy that utilizes the timely application of evidence-based medical and surgical concepts designed to maintain hemoglobin concentration, optimize hemostasis, and minimize blood loss in an effort to improve patient outcome. Various pharmacological and biological agents such as hematinics, hemostatic agents, coagulation factors and concentrates, and artificial oxygen carriers are available and/or under development to address this goal. Additionally, with new and complex medications available for use, especially modern anticoagulant therapies and their corresponding antidotes, it will be important for pharmacists and transfusion services to remain vigilant in staying up to date in order to best care for critically ill patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Erstad BL, Haas CE, O'Keeffe T, Hokula CA, Parrinello K, Theodorou AA. Interdisciplinary patient care in the intensive care unit: focus on the pharmacist. Pharmacotherapy. 2011;31(2):128–37.

    Article  Google Scholar 

  2. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing-2016. Am J Health Syst Pharm. 2017;74(17):1336–52.

    Article  Google Scholar 

  3. Preslaski CR, Lat I, MacLaren R, Poston J. Pharmacist contributions as members of the multidisciplinary ICU team. Chest. 2013;144(5):1687–95.

    Article  Google Scholar 

  4. Brilli RJ, Spevetz A, Branson RD, et al. Critical care delivery in the intensive care unit: defining clinical roles and the best practice model. Crit Care Med. 2001;29(10):2007–19.

    Article  CAS  Google Scholar 

  5. The American College of Emergency Physicians (ACEP). Clinical pharmacist Services in the Emergency Department. Ann Emerg Med. 2015;66:444–5.

    Google Scholar 

  6. Clinical Pharmacists in Oncology Practice. J Oncol Pract. 2008;4(4):172–4.

    Article  Google Scholar 

  7. Stucky ER. Prevention of medication errors in the pediatric inpatient setting. Pediatrics. 2003;112(2):431–6.

    Article  Google Scholar 

  8. ASHP Practice Advancement Initiative (PAI). http://www.ashpmedia.org/pai/. 2017. Accessed 1 Dec 2017.

  9. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: dispensing and administration—2014. Am J Health Syst Pharm. 2015;72(13):1119–37.

    Article  Google Scholar 

  10. Shander A, Nemeth J, Cruz JE, Javidroozi M. Patient blood management: a role for pharmacists. Am J Health Syst Pharm. 2017;74(1):e83–9.

    Article  Google Scholar 

  11. Shander A, Hofmann A, Isbister J, Van AH. Patient blood management--the new frontier. Best Pract Res Clin Anaesthesiol. 2013;27(1):5–10.

    Article  Google Scholar 

  12. Goodnough LT, Shander A. Patient blood management. Anesthesiology. 2012;116(6):1367–76.

    Article  Google Scholar 

  13. Shander A, Fink A, Javidroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev. 2011;25(3):232–46.

    Article  Google Scholar 

  14. Shander A, Gross I, Hill S, et al. A new perspective on best transfusion practices. Blood Transfus. 2013;11(2):193–202.

    PubMed  PubMed Central  Google Scholar 

  15. Burkiewicz JS, Zgarrick DP. Evidence-based practice by pharmacists: utilization and barriers. Ann Pharmacother. 2005;39(7–8):1214–9.

    Article  Google Scholar 

  16. Zuckerberg GS, Scott AV, Wasey JO, et al. Efficacy of education followed by computerized provider order entry with clinician decision support to reduce red blood cell utilization. Transfusion. 2015;55(7):1628–36.

    Article  Google Scholar 

  17. Farmer SL, Towler SC, Leahy MF, Hofmann A. Drivers for change: Western Australia patient blood management program (WA PBMP), world health assembly (WHA) and advisory committee on blood safety and availability (ACBSA). Best Pract Res Clin Anaesthesiol. 2013;27(1):43–58.

    Article  Google Scholar 

  18. Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. Anesth Analg. 2013;116(1):15–34.

    Article  CAS  Google Scholar 

  19. Shander A, Goodnough LT, Javidroozi M, et al. Iron deficiency anemia--bridging the knowledge and practice gap. Transfus Med Rev. 2014;28(3):156–66.

    Article  Google Scholar 

  20. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27(11):2346–50.

    Article  CAS  Google Scholar 

  21. Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2006;34(9):2310–6.

    Article  CAS  Google Scholar 

  22. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965–76.

    Article  CAS  Google Scholar 

  23. Shander A, Ozawa S, Gross I, Henry D. Erythropoiesis-stimulating agents: friends or foes? Transfusion. 2013;53(9):1867–72.

    Article  CAS  Google Scholar 

  24. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–33.

    Article  CAS  Google Scholar 

  25. Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion. 2008;48(5):988–1000.

    CAS  PubMed  Google Scholar 

  26. Lin DM, Lin ES, Tran MH. Efficacy and safety of erythropoietin and intravenous iron in perioperative blood management: a systematic review. Transfus Med Rev. 2013;27(4):221–34.

    Article  Google Scholar 

  27. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol. 2004;22(7):1301–7.

    Article  CAS  Google Scholar 

  28. Lasocki S, Longrois D, Montravers P, Beaumont C. Hepcidin and anemia of the critically ill patient: bench to bedside. Anesthesiology. 2011;114(3):688–94.

    Article  Google Scholar 

  29. Litton E, Baker S, Erber WN, et al. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicenter randomized blinded trial. Intensive Care Med. 2016;42:1715–22.

    Article  CAS  Google Scholar 

  30. Yang Q, Abudou M, Xie XS, Wu T. Androgens for the anaemia of chronic kidney disease in adults. Cochrane Database Syst Rev. 2014;10:CD006881.

    Google Scholar 

  31. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5(Suppl 1):132–42.

    Article  CAS  Google Scholar 

  32. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anaesth. 2006;53(6 Suppl):S2–11.

    Article  Google Scholar 

  33. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983;258(7):4249–56.

    CAS  PubMed  Google Scholar 

  34. Tranexamic Acid [package insert]. Princeton (NJ): Micro Labs Limited; 2016.

    Google Scholar 

  35. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319–31.

    Article  CAS  Google Scholar 

  36. Vonk AB, Meesters MI, Schats J, et al. Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery. Interact Cardiovasc Thorac Surg. 2011;12(2):135–9.

    Article  Google Scholar 

  37. Adler Ma SC, Brindle W, Burton G, et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2011;25(1):26–35.

    Article  CAS  Google Scholar 

  38. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096–101. 1101.

    Article  CAS  Google Scholar 

  39. Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth. 2009;56(3):202–12.

    Article  Google Scholar 

  40. Isgro F, Stanisch O, Kiessling AH, et al. Topical application of aprotinin in cardiac surgery. Perfusion. 2002;17(5):347–51.

    Article  Google Scholar 

  41. Emilia M, Luca S, Francesca B, et al. Topical hemostatic agents in surgical practice. Transfus Apher Sci. 2011;45(3):305–11.

    Article  Google Scholar 

  42. Carless PA, Henry DA, Anthony DM. Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev. 2009;1:CD004171.

    Google Scholar 

  43. Croxtall JD, Scott LJ. Recombinant human thrombin: in surgical hemostasis. BioDrugs. 2009;23(5):333–8.

    Article  CAS  Google Scholar 

  44. Kessler CM, Ortel TL. Recent developments in topical thrombins. Thromb Haemost. 2009;102(1):15–24.

    CAS  PubMed  Google Scholar 

  45. Higgins TS, Hwang PH, Kingdom TT, et al. Systematic review of topical vasoconstrictors in endoscopic sinus surgery. Laryngoscope. 2011;121(2):422–32.

    Article  Google Scholar 

  46. Moore PA, Hersh EV. Local anesthetics: pharmacology and toxicity. Dent Clin N Am. 2010;54(4):587–99.

    Article  Google Scholar 

  47. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1(4):682–9.

    Article  CAS  Google Scholar 

  48. Crescenzi G, Landoni G, Biondi-Zoccai G, et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology. 2008;109(6):1063–76.

    Article  CAS  Google Scholar 

  49. Ozier Y, Bellamy L. Pharmacological agents: antifibrinolytics and desmopressin. Best Pract Res Clin Anaesthesiol. 2010;24(1):107–19.

    Article  CAS  Google Scholar 

  50. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137(11):884–8.

    Article  CAS  Google Scholar 

  51. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154(8):529–40.

    Article  Google Scholar 

  52. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791–800.

    Article  CAS  Google Scholar 

  53. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171–7.

    Article  CAS  Google Scholar 

  54. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–87.

    Article  CAS  Google Scholar 

  55. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117(23):6091–9.

    Article  CAS  Google Scholar 

  56. Shander A, Goodnough LT. Why an alternative to blood transfusion? Crit Care Clin. 2009;25(2):261–77.

    Article  Google Scholar 

  57. Kocian R, Spahn DR. Haemoglobin, oxygen carriers and perioperative organ perfusion. Best Pract Res Clin Anaesthesiol. 2008;22(1):63–80.

    Article  CAS  Google Scholar 

  58. Chen JY, Scerbo M, Kramer G. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics (Sao Paulo). 2009;64(8):803–13.

    Article  Google Scholar 

  59. Sloan EP, Koenigsberg M, Gens D, et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA. 1999;282(19):1857–64.

    Article  CAS  Google Scholar 

  60. Kerner T, Ahlers O, Veit S, et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European “On-Scene” multicenter study. Intensive Care Med. 2003;29(3):378–85.

    Article  Google Scholar 

  61. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma. 2008;64(6):1484–97.

    Article  CAS  Google Scholar 

  62. Misra H, Lickliter J, Kazo F, Abuchowski A. PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial. Artif Organs. 2014;38(8):702–7.

    Article  CAS  Google Scholar 

  63. Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs. 2010;34(8):622–34.

    PubMed  Google Scholar 

  64. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299(19):2304–12.

    Article  CAS  Google Scholar 

  65. Hai CM. Systems biology of HBOC-induced Vasoconstrictio. Curr Drug Discov Technol. 2011;9(3):204–11.

    Article  Google Scholar 

  66. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after the use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg. 2010;110(3):685–93.

    Article  CAS  Google Scholar 

  67. Greenburg AG, Light WR, Dube GP. Reconstructing hemoglobin-based oxygen carriers. Transfusion. 2010;50(12):2764–7.

    Article  CAS  Google Scholar 

  68. Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah’s witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion. 2010;50(7):1561–7.

    Article  CAS  Google Scholar 

  69. Shander A, Moskowitz DM, Javidroozi M. Blood conservation in practice: an overview. Br J Hosp Med (Lond). 2009;70(1):16–21.

    Article  Google Scholar 

  70. Shander A, Javidroozi M. Strategies to reduce the use of blood products: a US perspective. Curr Opin Anaesthesiol. 2012;25(1):50–8.

    Article  CAS  Google Scholar 

  71. Shander A, Javidroozi M, Ashton ME. Drug-induced anemia and other red cell disorders: a guide in the age of polypharmacy. Curr Clin Pharmacol. 2011;6(4):295–303.

    Article  CAS  Google Scholar 

  72. Holzmacher JL, Sarani B. Indications and methods of anticoagulation reversal. Surg Clin North Am. 2017;97(6):1291–305.

    Article  Google Scholar 

  73. Idarucizumab (Praxbind) [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.

    Google Scholar 

  74. Holbrook A Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–84S.

    Article  Google Scholar 

  75. Prothrombin Complex Concentrate – Human (KCentra) [package insert]. Kankakee (IL): CSL Behring LLC; 2017.

    Google Scholar 

  76. Factor IX Complex (Profilnine) [package insert]. Los Angeles (CA): Grifols Biologicals Inc.; 2015.

    Google Scholar 

  77. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of Chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S–43S.

    Article  CAS  Google Scholar 

  78. Christos S, Naples R. Anticoagulation reversal and treatment strategies in major bleeding: update. West J Emerg Med. 2016;17(3):264–70.

    Article  Google Scholar 

  79. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206–32.

    Article  CAS  Google Scholar 

  80. Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol. 2016;95:437–49.

    Article  CAS  Google Scholar 

  81. Di Biase L. Use of direct oral anticoagulants in patients with atrial fibrillation and valvular hear lesions. J Am Heart Assoc. 2016;5(2).

    Google Scholar 

  82. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.

    Article  CAS  Google Scholar 

  83. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–41.

    Article  CAS  Google Scholar 

  84. Song Y, Wang Z, Perlstein I, et al. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. J Thromb Haemost. 2017;15(11):2125–37.

    Article  CAS  Google Scholar 

  85. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.

    Article  CAS  Google Scholar 

  86. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015;131(1):82–90.

    Article  CAS  Google Scholar 

  87. Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on non-vitamin K antagonist oral anticoagulants in the acute care and Periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017;135:e604–33.

    Article  CAS  Google Scholar 

  88. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413–24.

    Article  CAS  Google Scholar 

  89. Vogenberg FR, Gomes J. The changing roles of p&t committees: a look back at the last decade and a look forward to 2020. P T. 2014;39(11):760–72.

    Google Scholar 

  90. Haldiman L, Hamid Zia DO, Gurmukh Singh MD. Improving appropriateness of blood utilization through prospective review of requests for blood products: the role of pathology residents as consultants. 45, 3(1):1588–e647. Pages 264–271.

    Google Scholar 

  91. Ellingson KD, Sapiano MRP, Haass KA, et al. Continued decline in blood collection and transfusion in the United States-2015. Transfusion. 2017;57(Suppl 2):1588–98.

    Article  Google Scholar 

  92. Trueg AO, Lowe C, Kiel PJ. Clinical outcomes of a pharmacy-led blood factor stewardship program. Am J Ther. 2017;24(6):e643–7. https://doi.org/10.1097/MJT.0000000000000371.3.

    Article  PubMed  Google Scholar 

  93. Amerine LB, Chen SL, Daniels R, Key N, Eckel SF, Savage SW. Impact of an innovative blood factor stewardship program on drug expense and patient care. Am J Health Syst Pharm. 2015;72(18):1579–84. https://doi.org/10.2146/ajhp140722.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Englewood Hospital and Medical Center, Englewood, NJ, USA

    Joseph E. Cruz, Jeffrey Nemeth & Ana Burga

Authors
  1. Joseph E. Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Nemeth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Burga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph E. Cruz .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Team Health Research Institute, Englewood, NJ, USA

    Aryeh Shander

  2. Department of Critical Care Medicine, Geisinger Health System, Danville, PA, USA

    Howard L. Corwin

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cruz, J.E., Nemeth, J., Burga, A. (2018). Role of Blood Bank, Transfusion Services, and Pharmacy in ICU Patients with Hematologic Challenges. In: Shander, A., Corwin, H. (eds) Hematologic Challenges in the Critically Ill. Springer, Cham. https://doi.org/10.1007/978-3-319-93572-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93572-0_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93571-3

  • Online ISBN: 978-3-319-93572-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation